Compare TG Therapeutics Inc (TGTX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Value Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55.11 (market cap $8.16B), while Vanguard Value Index Fund ETF trades at $220.92 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 32.2× TG Therapeutics Inc's market cap, and Vanguard Value Index Fund ETF is more actively traded (3,293,281 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| TGTX | VTV | |
|---|---|---|
Market Cap | $8.16B | $262.40B |
Volume | 1,735,121 | 3,293,281 |
Sector | Health | — |
52-Week High | $59.06 | $227.51 |
52-Week Low | $26.94 | $182.86 |
Typical Hold Time | 16 Days | 142 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VTV trades at $220.55, up 1.07% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital Management and Blue Edge Capital. Recent news highlights value stocks outperforming growth in 2026, with VTV's 2.3% yield and low 0.03% fee attracting income-focused investors amid market rotation from tech.
The outlook remains mixed—technical indicators suggest near-term pressure, but strong institutional interest and value stock momentum support long-term stability. Key risks include underperformance versus broad market indices and sensitivity to interest rate changes. The dividend yield provides income cushion, yet investors should weigh VTV's value tilt against broader market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
